Our results indicated fluorescent BSAs were successfully delivered through CRISPRMAX into the breast cancer cells at high efficiency (65.4% at day 4 in BT-549, 65% at day 2 in MDA-MB-231, 78.1% at day 2 in Hs-578T) (Figure 2a,b). The gene discussed is HOXA1; the disease is breast cancer.